Novocure Withdraws Massive Gain On FDA Approval. Why It Could Struggle To Gain Traction. — Oct 16th, 2024

Novocure stock advanced, but pulled back from massive gains after the FDA signed off on its cancer treatment device. Continue reading View comments...

FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients — Oct 16th, 2024

FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients On Tuesday, the FDA approved NovoCure’s (NASDAQ:NVCR) Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel for adult patients with metastatic non...

FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients — Oct 16th, 2024

FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients On Tuesday, the FDA approved NovoCure’s (NASDAQ:NVCR) Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel for adult patients with metastatic non...

Novocure Withdraws Massive Gain On FDA Approval. Why It Could Struggle To Gain Traction. — Oct 16th, 2024

Novocure stock advanced, but pulled back from massive gains after the FDA signed off on its cancer treatment device. Continue reading View comments...

Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors — Oct 18th, 2024

Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board IRVINE, Calif., October 18, 2024--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI), a leading global medical innovator, today announced the appointm...

Novocure Stock Earns 96 RS Rating — Dec 3rd, 2024

On Tuesday, Novocure[ticker symb=NVCR] stock got a positive adjustment to its Relative Strength (RS) Rating, from 73 to 96. The oncology company had some good news Monday announcing success in its pancreatic cancer study. Continue reading View comments...

FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients — Oct 16th, 2024

FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients On Tuesday, the FDA approved NovoCure’s (NASDAQ:NVCR) Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel for adult patients with metastatic non...

Novocure Withdraws Massive Gain On FDA Approval. Why It Could Struggle To Gain Traction. — Oct 16th, 2024

Novocure stock advanced, but pulled back from massive gains after the FDA signed off on its cancer treatment device. Continue reading View comments...

Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors — Oct 18th, 2024

Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board IRVINE, Calif., October 18, 2024--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI), a leading global medical innovator, today announced the appointm...

Novocure Stock Earns 96 RS Rating — Dec 3rd, 2024

On Tuesday, Novocure[ticker symb=NVCR] stock got a positive adjustment to its Relative Strength (RS) Rating, from 73 to 96. The oncology company had some good news Monday announcing success in its pancreatic cancer study. Continue reading View comments...

Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors — Oct 18th, 2024

Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board IRVINE, Calif., October 18, 2024--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI), a leading global medical innovator, today announced the appointm...

Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors — Oct 18th, 2024

Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board IRVINE, Calif., October 18, 2024--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI), a leading global medical innovator, today announced the appointm...

NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains? — Oct 16th, 2024

NovoCure (NVCR) shares ended the last trading session 10.7% higher at $17.78. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 10.6% loss over the past four weeks. Shares of the company rallied af...

Novocure Stock Earns 96 RS Rating — Dec 3rd, 2024

On Tuesday, Novocure[ticker symb=NVCR] stock got a positive adjustment to its Relative Strength (RS) Rating, from 73 to 96. The oncology company had some good news Monday announcing success in its pancreatic cancer study. Continue reading View comments...

Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors — Oct 18th, 2024

Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board IRVINE, Calif., October 18, 2024--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI), a leading global medical innovator, today announced the appointm...

FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients — Oct 16th, 2024

FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients On Tuesday, the FDA approved NovoCure’s (NASDAQ:NVCR) Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel for adult patients with metastatic non...

Novocure Stock Earns 96 RS Rating — Dec 3rd, 2024

On Tuesday, Novocure[ticker symb=NVCR] stock got a positive adjustment to its Relative Strength (RS) Rating, from 73 to 96. The oncology company had some good news Monday announcing success in its pancreatic cancer study. Continue reading View comments...

NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains? — Oct 16th, 2024

NovoCure (NVCR) shares ended the last trading session 10.7% higher at $17.78. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 10.6% loss over the past four weeks. Shares of the company rallied af...

NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains? — Oct 16th, 2024

NovoCure (NVCR) shares ended the last trading session 10.7% higher at $17.78. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 10.6% loss over the past four weeks. Shares of the company rallied af...

Novocure shares soar 33% as FDA approves lung cancer treatment — Oct 16th, 2024

Investing.com -- Novocure Ltd (NASDAQ:NVCR) shares soared sharply after the announcement that the FDA had approved Optune Lua, a wearable device designed to treat certain types of lung cancer. The stock surged more than 33% in premarket trading Wednesday, after closing the Tuesday session...

NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains? — Oct 16th, 2024

NovoCure (NVCR) shares ended the last trading session 10.7% higher at $17.78. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 10.6% loss over the past four weeks. Shares of the company rallied af...

Novocure Stock Earns 96 RS Rating — Dec 3rd, 2024

On Tuesday, Novocure[ticker symb=NVCR] stock got a positive adjustment to its Relative Strength (RS) Rating, from 73 to 96. The oncology company had some good news Monday announcing success in its pancreatic cancer study. Continue reading View comments...

NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains? — Oct 16th, 2024

NovoCure (NVCR) shares ended the last trading session 10.7% higher at $17.78. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 10.6% loss over the past four weeks. Shares of the company rallied af...

Novocure shares soar 33% as FDA approves lung cancer treatment — Oct 16th, 2024

Investing.com -- Novocure Ltd (NASDAQ:NVCR) shares soared sharply after the announcement that the FDA had approved Optune Lua, a wearable device designed to treat certain types of lung cancer. The stock surged more than 33% in premarket trading Wednesday, after closing the Tuesday session...

Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors — Oct 18th, 2024

Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board IRVINE, Calif., October 18, 2024--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI), a leading global medical innovator, today announced the appointm...

Novocure Stock Earns 96 RS Rating — Dec 3rd, 2024

On Tuesday, Novocure[ticker symb=NVCR] stock got a positive adjustment to its Relative Strength (RS) Rating, from 73 to 96. The oncology company had some good news Monday announcing success in its pancreatic cancer study. Continue reading View comments...

Novocure Withdraws Massive Gain On FDA Approval. Why It Could Struggle To Gain Traction. — Oct 16th, 2024

Novocure stock advanced, but pulled back from massive gains after the FDA signed off on its cancer treatment device. Continue reading View comments...

NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains? — Oct 16th, 2024

NovoCure (NVCR) shares ended the last trading session 10.7% higher at $17.78. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 10.6% loss over the past four weeks. Shares of the company rallied af...

Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors — Oct 18th, 2024

Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board IRVINE, Calif., October 18, 2024--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI), a leading global medical innovator, today announced the appointm...

NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains? — Oct 16th, 2024

NovoCure (NVCR) shares ended the last trading session 10.7% higher at $17.78. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 10.6% loss over the past four weeks. Shares of the company rallied af...

Novocure Withdraws Massive Gain On FDA Approval. Why It Could Struggle To Gain Traction. — Oct 16th, 2024

Novocure stock advanced, but pulled back from massive gains after the FDA signed off on its cancer treatment device. Continue reading View comments...

Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors — Oct 18th, 2024

Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board IRVINE, Calif., October 18, 2024--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI), a leading global medical innovator, today announced the appointm...

Novocure Withdraws Massive Gain On FDA Approval. Why It Could Struggle To Gain Traction. — Oct 16th, 2024

Novocure stock advanced, but pulled back from massive gains after the FDA signed off on its cancer treatment device. Continue reading View comments...

Novocure Withdraws Massive Gain On FDA Approval. Why It Could Struggle To Gain Traction. — Oct 16th, 2024

Novocure stock advanced, but pulled back from massive gains after the FDA signed off on its cancer treatment device. Continue reading View comments...

FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients — Oct 16th, 2024

FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients On Tuesday, the FDA approved NovoCure’s (NASDAQ:NVCR) Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel for adult patients with metastatic non...

FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients — Oct 16th, 2024

FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients On Tuesday, the FDA approved NovoCure’s (NASDAQ:NVCR) Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel for adult patients with metastatic non...

Novocure shares soar 33% as FDA approves lung cancer treatment — Oct 16th, 2024

Investing.com -- Novocure Ltd (NASDAQ:NVCR) shares soared sharply after the announcement that the FDA had approved Optune Lua, a wearable device designed to treat certain types of lung cancer. The stock surged more than 33% in premarket trading Wednesday, after closing the Tuesday session...

Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors — Oct 18th, 2024

Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board IRVINE, Calif., October 18, 2024--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI), a leading global medical innovator, today announced the appointm...

Novocure Stock Earns 96 RS Rating — Dec 3rd, 2024

On Tuesday, Novocure[ticker symb=NVCR] stock got a positive adjustment to its Relative Strength (RS) Rating, from 73 to 96. The oncology company had some good news Monday announcing success in its pancreatic cancer study. Continue reading View comments...

Novocure shares soar 33% as FDA approves lung cancer treatment — Oct 16th, 2024

Investing.com -- Novocure Ltd (NASDAQ:NVCR) shares soared sharply after the announcement that the FDA had approved Optune Lua, a wearable device designed to treat certain types of lung cancer. The stock surged more than 33% in premarket trading Wednesday, after closing the Tuesday session...

NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains? — Oct 16th, 2024

NovoCure (NVCR) shares ended the last trading session 10.7% higher at $17.78. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 10.6% loss over the past four weeks. Shares of the company rallied af...

NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains? — Oct 16th, 2024

NovoCure (NVCR) shares ended the last trading session 10.7% higher at $17.78. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 10.6% loss over the past four weeks. Shares of the company rallied af...

Novocure shares soar 33% as FDA approves lung cancer treatment — Oct 16th, 2024

Investing.com -- Novocure Ltd (NASDAQ:NVCR) shares soared sharply after the announcement that the FDA had approved Optune Lua, a wearable device designed to treat certain types of lung cancer. The stock surged more than 33% in premarket trading Wednesday, after closing the Tuesday session...

Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors — Oct 18th, 2024

Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board IRVINE, Calif., October 18, 2024--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI), a leading global medical innovator, today announced the appointm...

Novocure shares soar 33% as FDA approves lung cancer treatment — Oct 16th, 2024

Investing.com -- Novocure Ltd (NASDAQ:NVCR) shares soared sharply after the announcement that the FDA had approved Optune Lua, a wearable device designed to treat certain types of lung cancer. The stock surged more than 33% in premarket trading Wednesday, after closing the Tuesday session...

FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients — Oct 16th, 2024

FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients On Tuesday, the FDA approved NovoCure’s (NASDAQ:NVCR) Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel for adult patients with metastatic non...

Novocure Stock Earns 96 RS Rating — Dec 3rd, 2024

On Tuesday, Novocure[ticker symb=NVCR] stock got a positive adjustment to its Relative Strength (RS) Rating, from 73 to 96. The oncology company had some good news Monday announcing success in its pancreatic cancer study. Continue reading View comments...

Novocure shares soar 33% as FDA approves lung cancer treatment — Oct 16th, 2024

Investing.com -- Novocure Ltd (NASDAQ:NVCR) shares soared sharply after the announcement that the FDA had approved Optune Lua, a wearable device designed to treat certain types of lung cancer. The stock surged more than 33% in premarket trading Wednesday, after closing the Tuesday session...

Novocure shares soar 33% as FDA approves lung cancer treatment — Oct 16th, 2024

Investing.com -- Novocure Ltd (NASDAQ:NVCR) shares soared sharply after the announcement that the FDA had approved Optune Lua, a wearable device designed to treat certain types of lung cancer. The stock surged more than 33% in premarket trading Wednesday, after closing the Tuesday session...

FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients — Oct 16th, 2024

FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients On Tuesday, the FDA approved NovoCure’s (NASDAQ:NVCR) Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel for adult patients with metastatic non...